(184 days)
- Permanent obturation of the root canal following vital pulp-extirpation.
- Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings.
- Suitable for use in single cone and lateral condensation technique.
EDS Bioceramic sealer (Bioseal) is a ready-to-use injectable bioceramic cement paste developed for permanent root canal filling and sealing applications. EDS Bioceramic Sealer (Bioseal) is an insoluble, radiopaque material based on a calcium silicate and calcium phosphate composition, which requires the presence of water to set and harden. EDS Bioceramic Sealer (Bioseal) does not shrink during setting. EDS Bioceramic Sealer (Bioseal) is packaged in a pre-loaded syringe and is supplied with disposable Intra Canal Tips.
Here's an analysis of the acceptance criteria and study information based on the provided document:
1. Table of Acceptance Criteria and Reported Device Performance
The document references compliance with ISO standards and specifications for performance and biocompatibility. The acceptance criteria are implicit in meeting these standards. The device performance is reported as meeting these standards.
| Acceptance Criteria Category | Specific Criteria (Implicitly met by compliance with standard) | Reported Device Performance (Summary from text) |
|---|---|---|
| Performance | ISO 6876:2012 (Flow, Setting time, Solubility, Radiopacity, Film thickness) | EDS Bioceramic Sealer (Bioseal) demonstrated equivalence in performance to the predicate device (EndoSequence BC Sealer) based on testing to these standards. |
| ANSI / ADA Specification No. 57 (Endodontic Sealing Materials) | EDS Bioceramic Sealer (Bioseal) demonstrated equivalence in performance. | |
| Biocompatibility | ISO 10993-1:2018 (Biological evaluation of medical devices) | EDS Bioceramic Sealer (Bioseal) is non-mutagenic, non-cytotoxic, does not elicit an allergenic response, and exhibits excellent tolerance by subcutaneous tissue. |
| ISO 10993-3:2014 (Genotoxicity, carcinogenicity, reproductive toxicity) | Non-mutagenic. | |
| ISO 10993-5:2009 (In vitro Cytotoxicity) | Non-cytotoxic. | |
| ISO 10993-6:2016 (Local effects after implantation) | Excellent tolerance by subcutaneous tissue. | |
| ISO 10993-10:2010 (Irritation and Skin Sensitization) | Does not elicit an allergenic response. | |
| ISO 10993-11:2017 (Systemic Toxicity) | (No specific detail, but implied as part of overall biocompatibility) | |
| Safety | ISO 14971:2007 (Application for risk management) | Equivalence in safety to the predicate device demonstrated through biocompatibility testing. |
2. Sample size used for the test set and the data provenance
The document does not specify the exact sample sizes for each bench test (Flow, Setting time, Solubility, Radiopacity, Film thickness) or for the biocompatibility tests. It broadly mentions "extensive bench (ISO 6876:2012) and biocompatibility testing."
The data provenance is not explicitly stated in terms of country of origin or whether it was retrospective/prospective. These were non-clinical, bench-top tests conducted by the manufacturer.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
This information is not provided. For non-clinical, bench-top tests, the "ground truth" is typically established by the testing methodology itself (e.g., measuring flow according to ISO 6876). Expert consensus in the traditional medical imaging sense (e.g., radiologists) is not applicable here.
4. Adjudication method for the test set
Not applicable. This device underwent bench and biocompatibility testing, not human reader studies requiring adjudication.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This is a root canal filling material, a medical device, and not an AI-powered diagnostic tool that human readers would use.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Not applicable. This is a root canal filling material, not an algorithm.
7. The type of ground truth used
For performance tests (Flow, Setting time, Solubility, Radiopacity, Film thickness), the ground truth is based on physical measurements and established parameters defined by the relevant ISO and ANSI/ADA standards.
For biocompatibility tests, the ground truth is derived from the results of the specific biological assays (e.g., cytotoxicity assays, genotoxicity assays) as per ISO 10993 series. These are objective laboratory measurements, not expert consensus, pathology, or outcomes data in the usual clinical sense.
8. The sample size for the training set
Not applicable. This device is not an AI/machine learning algorithm that requires a "training set." The materials and manufacturing processes are developed based on scientific principles and prior knowledge of similar materials, rather than iterative machine learning.
9. How the ground truth for the training set was established
Not applicable. As above, there is no "training set" for this type of medical device.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The FDA logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym along with the full name of the agency on the right. The Department of Health & Human Services logo features a stylized human figure, while the FDA part includes the acronym "FDA" in a blue square, followed by "U.S. FOOD & DRUG" and "ADMINISTRATION" in blue text.
February 12, 2021
Essential Dental Systems Jason Guzman R&D Manager 89 Leuning Street South Hackensack, New Jersey 07606
Re: K202281
Trade/Device Name: EDS Bioceramic Sealer (Bioseal) Regulation Number: 21 CFR 872.3820 Regulation Name: Root Canal Filling Resin Regulatory Class: Class II Product Code: KIF Dated: December 21, 2020 Received: December 22, 2020
Dear Jason Guzman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
{1}------------------------------------------------
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Michael E. Adjodha, M.ChE. Assistant Director DHT1B: Division of Dental Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K202281
Device Name EDS Bioceramic Sealer (Bioseal)
Indications for Use (Describe)
-
Permanent obturation of the root canal following vital pulp-extirpation.
-
Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings.
-
Suitable for use in single cone and lateral condensation technique.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Section 5 - 510(k) Summary
[21 CFR 807.92 (c)]
| 1. | Application Information: [807.92 (a)(1)] | ||
|---|---|---|---|
| Date Prepared: July 6, 2020 | |||
| Company Name and Address: | Essential Dental Systems89 Leuning Street, South Hackensack, NJ 07606 | ||
| Contact: | Mr. Jason Guzman | Ms. Shamal Kadam | |
| Designation: | R&D Manager | Regulatory Affairs Specialist | |
| Email: | jguzman@edsdental.com | skadam@edsdental.com | |
| Phone #: | 201-487-9090 (ext.119) | 201-487-9090 (ext.114) | |
| Fax #: | 201-487-5120 | 201-487-5120 | |
| List of devices for which clearance is requested: | Root canal sealing material called EDS Bioceramic Sealer (Bioseal) |
2. Name of the Device: [807.92 (a)(2)]
| Trade name: | EDS Bioceramic Sealer (Bioseal) |
|---|---|
| Device Type: | Resin, Root Canal Filling |
| Regulation Description: | Root Canal Filling Resin |
| Review Panel: | Dental |
| Regulation Number: | 21 CFR 872.3820 |
| Device class: | Class II |
| Product Code: | KIF |
3. Predicate Device Information: [807.92 (a)(3)]
The legally marketed devices to which substantial equivalence is being claimed are:
Table 5A - Predicate Devices
| Device | Manufacturer | 510K number | |
|---|---|---|---|
| 1. | EndoSequence BC Sealer | Brasseler | K120048 |
| 2. | ProSmart Root Canal Obturation System | DRFP | K100248 |
4. Device Description: [807.92 (a)(4)]
EDS Bioceramic sealer (Bioseal) is a ready-to-use injectable bioceramic cement paste developed for permanent root canal filling and sealing applications. EDS Bioceramic Sealer (Bioseal) is an insoluble, radiopaque material based on a calcium silicate and calcium phosphate composition, which requires the presence of water to set and harden. EDS Bioceramic Sealer (Bioseal) does
{4}------------------------------------------------
not shrink during setting. EDS Bioceramic Sealer (Bioseal) is packaged in a pre-loaded syringe and is supplied with disposable Intra Canal Tips.
5. Device Configuration: [807.92 (a)(4)]
lt consists of two component pastes that are combined in a dual barrel syringe for ease of dispensing and consistent dosage. It is used in combination with gutta-percha points during root canal obturation. It is packaged in the familiar double-barrel syringe configuration used by numerous other dental materials. The steps required to properly express the cement are: remove cap, attach mixer, attach dispensing top, press plunger. After use, the mixer / dispensing tip should be discarded and the cap replaced. The device is provided non-sterile.
6. Device Composition:
- -Calcium Silicates
- -Zirconium Oxide
- -Calcium Hydroxide
- -Halloysite clay
- -Polyacrylic acid
- -Bioactive Glass (45S5)
- -Calcium Phosphate Monobasic
- β-Tricalcium Phosphate
- -Silica thickening Agents
- Chlorhexidine -
- -Polyethylene glycol (MW 300)
7. Intended Use: [807.92 (a)(5)]
The EDS Bioceramic Sealer (Bioseal) is indicated for permanent sealing of root canals following established endodontic procedures. Permanent obturation of the root canal following vital pulpextirpation or removal of infected or necrotic pulp followed by the placement of intra-canal dressings. The EDS Bioceramic Sealer (Bioseal) is suitable for use in single cone and lateral condensation technique.
8. Indications for Use: [807.92 (a)(5)]
- l Permanent obturation of the root canal following vital pulp-extirpation.
- . Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings.
- l Suitable for use in single cone and lateral condensation technique.
{5}------------------------------------------------
9. Substantial Equivalence Discussion: [807.92 (a)(6)]
A comparison of EDS Bioceramic Sealer (Bioseal) and the predicate devices indicates the following similarities and differences to the devices which received 510(k) clearance:
| Proposed Device | Primary Predicate Device | Reference PredicateDevice | |
|---|---|---|---|
| Device Name | EDS Bioceramic Sealer(Bioseal) | EndoSequence BC Sealer | ProSmart Root CanalObturation System |
| 510(k)Number | K202281 | K120048 | K100248 |
| Manufacturer | Essential Dental Systems | Brasseler | DRFP |
| Indications forUse | Permanent obturationof the root canalfollowing vital pulp-extirpation.Permanent obturationof the root canalfollowing removal ofinfected or necroticpulp and placement ofintracanal dressings.Suitable for use insingle cone and lateralcondensationtechnique. | Permanent obturationof the root canalfollowing vital pulp-extirpation.Permanent obturationof the root canalfollowing removal ofinfected or necroticpulp and placement ofintracanal dressings.Suitable for use insingle cone and lateralcondensationtechnique. | Permanent obturationof the root canalfollowing vital pulp-extirpation.Permanent obturationof the root canalfollowing removal ofinfected or necroticpulp and placement ofintracanal dressings.Suitable for use insingle cone and lateralcondensationtechnique. |
| Composition | Calcium Silicates, CalciumPhosphate monobasic, β-Tricalcium Phosphate,Zirconium Oxide,Polyethylene glycol (MW300), Calcium Hydroxide,silica thickening agents.Bioactive Glass (45S5),Polyacrylic acid,Chlorhexidine, Halloysiteclay. | Calcium Silicates, CalciumPhosphates, ZirconiumOxide, Polyethylene glycol,Calcium Hydroxide, Fillerand Silica ThickeningAgents. | Epoxy-Amine Resin,Hydrophilic Polymers,Calcium Hydroxide, MetalOxides, Filler andThickening Agents. |
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image is a logo for Essential Dental Systems. The logo is in blue and white and features the letters "EDS" in a stylized font. To the right of the letters is the text "ESSENTIAL DENTAL SYSTEMS" in a smaller font. The logo is enclosed in a rounded rectangle.
Essential Dental Systems, Inc.
Essential Dental Systems, inc.
Essential Dental Systems, inc. 89 Leuning Street, South Hackensack, NJ 07606
Submission Number: K202281 EDS Bioceramic Sealer (Bioseal) Traditional 510(k) - Original
| Proposed Device | Primary Predicate Device | Reference PredicateDevice | |
|---|---|---|---|
| Shades | White | White | White |
| TissueContactingDeviceMaterial(s) | Calcium Silicates, CalciumPhosphate monobasic, β-Tricalcium Phosphate,Zirconium Oxide,Polyethylene glycol (MW300), Calcium Hydroxide,Silica thickening agents.Bioactive Glass (45S5),Polyacrylic acid,Chlorhexidine, Halloysiteclay. | Zirconium Oxide, CalciumPhosphates, TricalciumSilicate, Dicalcium Silicate,Calcium Hydroxide,Polyethylene glycol, SilicaFiller, and Silica ThickeningAgents. | Calcium Phosphate, Epoxy- Amine Resin, Silica Filler,and Thickening Agents. |
| DeviceDescription | EDS Bioceramic sealer(Bioseal) is a ready-to-useinjectable bioceramiccement paste developedfor permanent root canalfilling and sealingapplications. EDSBioceramic Sealer(Bioseal) is an insoluble,radiopaque materialbased on a calciumsilicate and calciumphosphate composition,which requires thepresence of water to setand harden. EDSBioceramic Sealer(Bioseal) does not shrinkduring setting. EDSBioceramic Sealer(Bioseal) is packaged in apre-loaded syringe and issupplied with disposableIntra Canal Tips. | Premixed ready-to-useinjectable white hydrauliccement paste developedfor permanent root canalfilling and sealingapplications. It is based ona primarily calciumsilicate/calcium phosphatecomposition and requiresthe presence of water toset and harden. Suppliedin a single barrel syringe. | The ProSmart useshydrophylic polymerswhich allows the materialto expand intoirregularities and tubulesof the root canal to assurea tight mechanical sealwith the dentin. |
{7}------------------------------------------------
Image /page/7/Picture/0 description: The image is a logo for Essential Dental Systems (EDS). The logo is in blue and consists of the letters "EDS" in a stylized font, with the words "ESSENTIAL DENTAL SYSTEMS" to the right of the letters. The logo is enclosed in a rounded rectangle.
C Essential Denta Essential Dental Systems, inc. 89 Leuning Street, South Hackensack, NJ 07606
Submission Number: K202281 EDS Bioceramic Sealer (Bioseal) Traditional 510(k) - Original
| Proposed Device | Primary Predicate Device | Reference PredicateDevice | |
|---|---|---|---|
| Picture ofDevice | Image: Proposed Device | Image: Primary Predicate Device | Image: Reference Predicate Device |
| Intended Use | Endsequence BC Sealer isintended for permanentsealing of root canalsfollowing establishedendodontic proceduresby qualified healthcareprofessionals. | Endsequence BC Sealer isintended for permanentsealing of root canalsfollowing establishedendodontic procedures byqualified healthcareprofessionals. | The ProSmart is designedfor the permanent sealingof root canals followingestablished endodonticprocedures by qualifiedhealthcare professionals. |
| TechnologyComparison | EDS Bioceramic Sealer(Bioseal) uses a dualsyringe system to ensurean equal 1:1 mixing of thetwo hydraulic pastecomposition. Thecomposition containsabsorbant halloysite claysin order to ensurehydration / efficientsetting of the cement.The subject device,contains further agentsthat serve as additionalion sources. Theseinclude bioactive glass(45S5) as well as differentforms of calciumphosphates (monobasiccalcium phosphate, β Tri-calcium phosphate). Asthese ion richcomponents becomehydrated in the rootcanal, they further | The EndoSequence comesPre-mixed and ready-to-use injectable whitehydraulic cement paste ina single barrel syringe. TheEndoSequence bioceramicsealer is based on acalcium silicate / calciumphosphate compositionand requires water to setand harden. | The DRFP ProSmart comeswith its two - componentcatalyst paste based onepoxy-amine resinchemistry. The pasteadditionally comes with an"active powder" that mustbe mixed to provide thepaste with its hydrophilicproperties to allow themixture to expand intocrevices and dentinetubules. |
{8}------------------------------------------------
Image /page/8/Picture/0 description: The image is a logo for Essential Dental Systems (EDS). The logo is in blue and consists of the letters "EDS" in a bold, stylized font. To the right of the letters, the words "ESSENTIAL DENTAL SYSTEMS" are stacked vertically. The logo is enclosed in a rounded rectangle with a registered trademark symbol in the upper right corner.
C Essential Dental Essential Dental Systems, inc. 89 Leuning Street, South Hackensack, NJ 07606
| Proposed Device | Primary Predicate Device | Reference Predicate Device |
|---|---|---|
| contribute to the precipitation/formation of a hard mineral phase that structurally reinforces the endodontically treated tooth over time. The addition of trace amounts of chlorhexidine and poly acrylic acid aid in the stabilization and coordination of precipitated calcium and other ions via electrostatic interactions. These stabilized / precipitated ions aid in the sealing of the root canal system. |
| Differences | The EDS BioceramicSealer (Bioseal) issupplied with a twobarrel syringe deliverysystem in order to ensureproper mixing. Thecomposition containsabsorbant halloysite claysin order to ensurehydration / efficientsetting of the cement.The subject device,contains further agentsthat serve as additionalion sources. Theseinclude bioactive glass(45S5) as well as differentforms of calcium | Delivered in a single barrelsyringe delivery system. | Two-component catalystpaste based on epoxy-amine resin chemistry. Thepaste additionally comeswith an "active powder"that must be mixed byhand and applied. |
|---|---|---|---|
| ------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
{9}------------------------------------------------
Image /page/9/Picture/0 description: The image is a logo for Essential Dental Systems. The logo is in blue and consists of the letters "EDS" in a stylized font, with the words "ESSENTIAL DENTAL SYSTEMS" to the right of the letters. The logo is enclosed in a rounded rectangle. There is a registered trademark symbol in the upper right corner of the rectangle.
Essential D Essential Dental Systems, inc. 89 Leuning Street, South Hackensack, NJ 07606
| phosphates (monobasiccalcium phosphate, β Tri-calcium phosphate). Asthese ion richcomponents becomehydrated in the rootcanal, they furthercontribute to theprecipitation/formationof a hard mineral phasethat structurallyreinforces theendodontically treatedtooth over time. Theaddition of trace amountsof chlorhexidine and polyacrylic acid aid in thestabilization andcoordination ofprecipitated calcium andother ions viaelectrostatic interactions.Thesestabilized/precipitatedions aid in the sealing ofthe root canal system. | |
|---|---|
| ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -- |
{10}------------------------------------------------
Similarities and Differences:
The EDS Bioceramic Sealer (Bioseal) is similar to the predicate devices EndoSequence BC Sealer (K120048) and ProSmart Root Canal Obturation System (K100248). These are available as radiopaque pastes essentially designed for equivalent dental applications and have comparable physical properties, performance specifications and share specific chemical components. The principal composition of the EDS Bioceramic Sealer (Bioseal) is based on EndoSequence BC Sealer (K120048). Both the aforementioned predicate devices contain specific chemical components that are identical or equivalent to those found in the EDS Bioceramic Sealer (Bioseal). The subject device, however, contains further agents that serve as additional ion sources that contribute to the sealing of the root canal. These include bioactive glass (4555) as well as different forms of calcium phosphates (monobasic calcium phosphate, β Tri-calcium phosphate). As these ion rich components become hydrated in the root canal, they further contribute to the precipitation/formation of a hard mineral phase that structurally reinforces the endodontically treated tooth over time. The addition of trace amounts of chlorhexidine and poly acrylic acid aid in the stabilization and coordination of precipitated calcium and other ions via electrostatic interactions. While these are some of the differences between the subject device and predicate device EndoSequence BC Sealer (K120048), the vast majority of the both compositions are primarily composed of calcium silicates, zirconium oxide, and low molecular weight polyethylene glycol which accounts for well over 90% of the composition. Both compositions, the subject and predicate devices, utilize polyethylene glycol as a nonaqueous liquid carrier where all of the other components are suspended to yield a flowable-injectable paste. Both devices have identical indications for use as root canal sealers. While the subject device has some additional additives, the technological characteristics, mode and mechanism of action for both devices, subject device and predicate device, are identical. All of the components found in the predicate devices have been used in legally marketed devices and were for dental use. We believe that prior use of components in legally marketed devices, the performance and biocompatibility data provided support the safety and effectiveness of the EDS Bioceramic Sealer (Bioseal) for the indicated uses.
10. Discussion of Non-Clinical Tests Performed for Determination of Substantial Equivalence are as Follows: [807.92 (b)(1)]
The EDS Bioceramic Sealer (Bioseal) has undergone extensive bench (ISO 6876:2012) and biocompatibility testing to provide evidence that the physical and chemical properties of the composition are substantially equivalent to EndoSequence BC Sealer (K120048). Bench tests included:
- | Flow
- Setting time -
- -Solubility
- -Radiopacity
- Film thickness -
{11}------------------------------------------------
The legally marketed and extensively tested EndoSequence BC Sealer (K120048) shows that it is exceptionally biocompatible and safe for the intended use. Since the chemical composition of EDS Bioceramic Sealer (Bioseal) is based on EndoSequence BC Sealer (K120048), the biocompatibility test data provides further evidence of biocompatibility and over all safety. The results of the biocompatibility testing shows that the EDS Bioceramic Sealer (Bioseal) is non-mutagenic, noncytotoxic and does not elicit an allergenic response while exhibiting excellent tolerance by the subcutaneous tissue.
Testing of biocompatibility and physical properties were conducted to determine equivalence of the EDS Bioceramic Sealer (Bioseal) [K202281] to the predicate device EndoSequence BC Sealer [K120048].
Safety:
Equivalence in safety to the predicate device is demonstrated by the results of six biocompatibility tests performed according to ISO 10993, as follows:
| ▪ ISO 14971:2007 | - | Medical Devices - Application for risk management to medical devices |
|---|---|---|
| ▪ ISO 10993-1:2018 | - | Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process |
| ▪ ISO 10993-3:2014 | - | Biological Evaluation of Medical Devices - Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity |
| ▪ ISO 10993-5:2009 | - | Biological evaluation of medical devices - Part 5. Tests for in vitro Cytotoxicity and implantation |
| ▪ ISO 10093-6:2016 | - | Biological evaluation of medical devices - Part 6: Tests for local effects after implantation |
| ▪ ISO 10993-10:2010 | - | Biological Evaluation Of Medical Devices - Part 10: Tests For Irritation And Skin Sensitization |
| ▪ ISO 10993-11:2017 | - | Biological Evaluation of Medical Devices - Part 11: Tests for Systemic Toxicity |
Performance:
Testing of physical properties according to the following standards have demonstrated equivalence in performance to the predicate device.
| ■ ISO 6876:2012 | - | Dentistry – Root Canal Sealing Materials |
|---|---|---|
| ■ ISO 7405:2018 | - | Dentistry – Evaluation of biocompatibility of medical devicesused in dentistry |
| ■ ANSI / ADASpecification No. 57 | - | Endodontic Sealing Materials |
{12}------------------------------------------------
11. Discussion of Clinical Tests Performed: [807.92 (b)(2)]
There was no clinical testing required to support the medical device as the indications for use is equivalent to the predicate device. These types of devices, including the predicate devices, have been on the market for many years with a proven safety and efficacy for the use of the device. The verification and validation testing of the device was found to be acceptable and supports the claims of substantial equivalence.
12. Conclusions: [807.92 (b)(3)]
The EDS Bioceramic Sealer (Bioseal) is substantially equivalent in terms of performance, indications for use, and biocompatibility to the cleared and marketed predicate devices EndoSequence BC Sealer (K120048) and ProSmart Root Canal Obturation System (K100248). Any technological differences between the EDS Bioceramic Sealer (Bioseal) and the predicate device(s) do not raise any questions regarding the safety and effectiveness of the subject device.
The information provided in this submission supports the substantial equivalence to the predicate device(s) and that the system is safe and effective for the users/operators.
§ 872.3820 Root canal filling resin.
(a)
Identification. A root canal filling resin is a device composed of material, such as methylmethacrylate, intended for use during endodontic therapy to fill the root canal of a tooth.(b)
Classification. (1) Class II if chloroform is not used as an ingredient in the device.(2) Class III if chloroform is used as an ingredient in the device.
(c)
Date PMA or notice of completion of a PDP is required. A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any root canal filling resin described in paragraph (b)(2) of this section that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a root canal filling resin described in paragraph (b)(2) of this section that was in commercial distribution before May 28, 1976. Any other root canal filling resin shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.